SNDX SYNDAX PHARMACEUTICALS INC Product Launches 8-K Filing 2023 - Product Updates On July 24, 2023, Syndax Pharmaceuticals, Inc. announced the topline results from its pivotal clinical trial, AGAVE-201, of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD). The company also plans to hold a conference call regarding the announcement.Get access to all SEC 8-K filings of the SYNDAX PHARMACEUTICALS INC